Student Research Committee, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Sci Rep. 2021 May 24;11(1):10786. doi: 10.1038/s41598-021-90228-0.
Lipid goal achievement and statin consumption were estimated at extreme/very-high/high/moderate and low cardiovascular risk categories. In the cross-sectional study, 585 patients treated with statin therapy referring to the heart clinic of Birjand were recruited. Patients were classified and examined LDL-C values and the proportion reaching targets according to the American Association of Clinical Endocrinologists guideline. Three patterns of statin use (high/moderate/low-intensity statin therapy) in all patients were examined and attainments of LDL-C goal in cardiovascular risk groups have been demonstrated. Over half the populations (57.6%) were in the very-high CVD risk group. The results showed that the proportion of patients meeting total LDL-C goal values according to the guidelines was 43.4%. The frequency of patient had achievement LDL goal lower in high-intensity pattern (N = 13, 2.3%), compared with moderate (N = 496, 86.1%) and low-intensity patterns (N = 67, 11.6%). In general, LDL-C goal achievement was greatest with moderate-intensity statin use. LDL-C reduction after statin consumption was estimated about one-third of the studied population. It seems likely that the achievement of a therapeutic target for serum lipids such as LDL-C improved is far more cost-effective and would be able to reach the target LDL as well changing the type and intensity of statins.
在心血管风险极低/低、低/中、中/高和极高/极高风险类别中,评估了血脂目标的实现和他汀类药物的使用情况。在这项横断面研究中,共招募了 585 名在比詹德心脏诊所接受他汀类药物治疗的患者。根据美国临床内分泌医师协会指南对患者进行分类和检查 LDL-C 值,并根据指南检查了所有患者中他汀类药物的三种使用模式(高强度/中强度/低强度他汀类药物治疗),并证明了在心血管风险组中达到 LDL-C 目标的情况。超过一半的人群(57.6%)处于极高 CVD 风险组。结果表明,根据指南,符合总 LDL-C 目标值的患者比例为 43.4%。与中强度(N=496,86.1%)和低强度(N=67,11.6%)模式相比,高强度模式(N=13,2.3%)的患者达到 LDL 目标的比例较低。总体而言,中等强度他汀类药物的使用使 LDL-C 目标的实现率最高。他汀类药物治疗后 LDL-C 降低估计约占研究人群的三分之一。似乎更有可能的是,通过改变他汀类药物的类型和强度来实现治疗性血脂目标(如 LDL-C)的改善,将更具成本效益,并且能够达到目标 LDL。